Log In

Forgot Password?
Create New Account

Loading... please wait

2014 Annual Meeting | Revolution of Genetic Tools and the Impact on Neurology

Tuesday 04/29/14
01:00 PM - 05:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Integrated Neuroscience
Petra Kaufmann, MD, FAAN, Mark F. Mehler, MD, FAAN
General Neurology, Research Methodology, Education, and History
Participants should be more familiar with novel genetic tools, with the potential benefits and limitations of using the resulting datasets in neurological diagnosis, and with some of the associated ethical and practical issues.
No CME available
Other, Trainee, General Neurologist, Specialist Neurologist, Non-neurologist
Interactive, Audience Participation
Event Timeline
01:00 PM - 01:25 PM Advances in Epigenetics and its Implications for Understanding and Treating Neurological Disorders
Mark F. Mehler, MD, FAAN
01:00 PM - 05:00 PM Abstract 001 - Exome Sequencing Identifies PINCH2 Mutations in Early Onset Autosomal Recessive LGMD with Severe Cardiomyopathy and Triangular Tongues
01:00 PM - 05:00 PM Abstract 001 - Late-onset Alzheimer disease neuropathology genomic screen identifies novel loci for neuritic plaque and other AD neuropathology features
Gary W. Beecham, PhD
01:00 PM - 05:00 PM Abstract 002 - Genetic & Neuroanatomic Associations in Sporadic Frontotemporal Lobar Degeneration
Corey McMillan, PhD
01:00 PM - 05:00 PM Abstract 002 - The TREM2 Variant p.R47H is a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis
Matthew Harms, MD
01:00 PM - 05:00 PM Abstract 003 - Transcript profiling analysis of Alzheimer's disease brains.
Mariet Allen, PhD
01:00 PM - 05:00 PM Abstract 003 - TIGAR Inhibition Rescues Dopaminergic Neurons in Common Forms of Early Onset Parkinson's' Disease
Oliver E. Bandmann, MD, PhD, FAAN
01:00 PM - 05:00 PM Abstract 004 - Novel Mutation in VCP Causes Charcot-Marie-Tooth Type 2 (CMT2) Phenotype
Shawna Feely, MS, CGC
01:00 PM - 05:00 PM Abstract 004 - Investigation of transcriptional regulation at the Alzheimer's disease risk loci.
Michaela Kachadoorian
01:00 PM - 05:00 PM Abstract 005 - GCH1 Heterozygous Mutation Identified by Whole-Exome-Sequencing as a Treatable Condition in a Patient Presenting with Progressive Spastic Paraplegia
Zheng Fan, MD
01:00 PM - 05:00 PM Abstract 005 - Spinal muscular atrophy phenotype is ameliorated either by SMN increase or modulation of secondary cell death events with RNA therapy
01:00 PM - 05:00 PM Abstract 006 - Structural and Functional Implications of Modeling Non Synonymous Mutations in Patients with SCN1A-related Seizure Disorders
Mu Gao
01:00 PM - 05:00 PM Abstract 007 - The Dissection of High-Penetrance Variants in extended Late-Onset Alzheimer Disease Families by Whole-Exome Sequencing
Martin A. Kohli
01:00 PM - 05:00 PM Abstract 008 - TMEM106B is a Genetic Modifier of Frontotemporal Lobar Degeneration with C9orf72 Hexanucleotide Repeat Expansions
Alice Chen-Plotkin, MD
01:00 PM - 05:00 PM Abstract 009 - Expression QTL studies in LOAD and PSP brains by next-generation RNA sequencing
Nilufer Taner, MD, PhD, FAAN
01:25 PM - 01:50 PM How Gene Networks and Systems Biology Informs Our Understanding of Nervous System Disease
Daniel H. Geschwind, MD, PhD
01:50 PM - 02:15 PM New Genetic Tools and Their Impact on the Diagnosis of Neuromuscular Disorders
Kenneth H. Fischbeck, MD, FAAN
02:15 PM - 02:40 PM Clinical Whole-Exome Sequencing in the Diagnosis of Mendelian Disorders of the CNS
Arthur Beaudet, MD
02:40 PM - 03:05 PM Using Genomics in Routine Clinical Care
Teri Manolio, MD, PhD
03:05 PM - 03:30 PM Advances in Genetics and Impact on the Treatment of Neurological Disease
Beverly Davidson, PhD
03:30 PM - 04:30 PM Poster Rounds/Panel Discussion
04:30 PM - 05:00 PM Data Blitz
Faculty Disclosures
Petra Kaufmann, MD, FAAN Dr. Kaufmann has received personal compensation for serving as an employee of Novartis Gene Therapies. Dr. Kaufmann has received personal compensation for serving as an employee of Affinia Therapeutics.
Mark F. Mehler, MD, FAAN No disclosure on file
Daniel H. Geschwind, MD, PhD Dr. Geschwind has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Ovid Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AcuraStem, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axial Biotherapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Falcon Computing. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier-Biological Psychiatry. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NYAS. Dr. Geschwind has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Covington& Burling LLP. Dr. Geschwind has stock in none related to talk. The institution of Dr. Geschwind has received research support from CurePSP. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from Rainwater Charitable Foundation. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from The Simons Foundation. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NINDS. The institution of Dr. Geschwind has received research support from NIMH. The institution of Dr. Geschwind has received research support from NINDS/NIA. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from NIH/NINDS. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH/NIMH. The institution of Dr. Geschwind has received research support from Adelson Medical Research Foundation. The institution of Dr. Geschwind has received research support from U of Virginia and NIH/NIMH. The institution of Dr. Geschwind has received research support from NIH. The institution of Dr. Geschwind has received research support from NIH/NHGRI. The institution of Dr. Geschwind has received research support from NIH/NIMH. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care. Dr. Geschwind has received intellectual property interests from a discovery or technology relating to health care.
Kenneth H. Fischbeck, MD, FAAN Dr. Fischbeck has received research support from NINDS/NIH. Dr. Fischbeck has received intellectual property interests from a discovery or technology relating to health care. Dr. Fischbeck has a non-compensated relationship as a Scientific Review Board member with Kennedy's Disease Association that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a Scientific Council member with Association Francaise contre les Myopathies that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a Independent Review Committee member with Target ALS that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a Scientific Advisory Board member, Musculoskeletal Diseases with Novartis that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a Senior Clinical Consultant with n-Lorem Foundation that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a Scientific Advisory Committee member with Stanford GNE myopathy program that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a Scientific Advisory Board member with Hereditary Disease Foundation that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a Scientific Advisory Board member with Packard Center for ALS Research that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a Scientific Advisory Board member with Huntington's Disease Society of America that is relevant to AAN interests or activities. Dr. Fischbeck has a non-compensated relationship as a TACT review panel member with TREAT-NMD that is relevant to AAN interests or activities.
Arthur Beaudet, MD No disclosure on file
Beverly Davidson, PhD No disclosure on file
Teri Manolio, MD, PhD No disclosure on file
Robert S. Greenwood, MD, FAAN No disclosure on file
Neill R. Graff-Radford, MD, FAAN The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Novartis. The institution of Dr. Graff-Radford has received research support from AbbVie. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.
Nilufer Taner, MD, PhD, FAAN The institution of Dr. Taner has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nestle. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Stephan Zuchner, MD, FAAN Dr. Zuchner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Therapeutics. The institution of Dr. Zuchner has received research support from Muscular Dystrophy Association. The institution of Dr. Zuchner has received research support from CMT Association. Dr. Zuchner has received intellectual property interests from a discovery or technology relating to health care.
Margaret A. Pericak-Vance, PhD Dr. Pericak-Vance has nothing to disclose.
Virginia Lee, PhD Virginia Lee, PhD has nothing to disclose.
Dennis W. Dickson, MD Dr. Dickson has nothing to disclose.
Murray Grossman, MD, FAAN Dr. Grossman has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Grossman has received research support from NIH.
No disclosure on file
Mariet Allen, PhD No disclosure on file
Stanley H. Appel, MD, FAAN Dr. Appel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Appel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eledon. The institution of Dr. Appel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Implicit. The institution of Dr. Appel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Coya Therapeutics. Dr. Appel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Muscular Disease Association. Dr. Appel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for ALS Therapy Development Institute. Dr. Appel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for ALS Finding a Cure. Dr. Appel has stock in Stock holdings in retirement acct at Fidelity. The institution of Dr. Appel has received research support from Coya Therapeutics.
Serena Pagliarani No disclosure on file
Elisabeth M. Wood, MSCGC No disclosure on file
Francesca Magri No disclosure on file
Oliver E. Bandmann, MD, PhD, FAAN No disclosure on file
Minerva Carrasquillo Minerva Carrasquillo has nothing to disclose.
Lauren B. Elman, MD Dr. Elman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Elman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche/Genentech. Dr. Elman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Edgewise Therapeutics. Dr. Elman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Dr. Elman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apellis Pharamaceuticals. Dr. Elman has received publishing royalties from a publication relating to health care.
John Q. Trojanowski, MD, PhD Dr. Trojanowski has nothing to disclose.
Nereo Bresolin, DR No disclosure on file
Alison Goate, PhD No disclosure on file
Robert H. Baloh, MD, PhD, FAAN Dr. Baloh has received personal compensation for serving as an employee of Roche. Dr. Baloh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Acurastem. Dr. Baloh has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Irell. The institution of Dr. Baloh has received research support from NIH and CIRM.
Leo McCluskey, MD No disclosure on file
Timothy M. Miller, MD, PhD Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ionis Pharmaceuticals. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Disarm Therapeutics. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen IDEC. Dr. Miller has received intellectual property interests from a discovery or technology relating to health care. Dr. Miller has received intellectual property interests from a discovery or technology relating to health care.
Michael E. Shy, MD, FAAN Dr. Shy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Therapeutics. The institution of Dr. Shy has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for DTx Pharma. The institution of Dr. Shy has received research support from NIH. The institution of Dr. Shy has received research support from Muscular Dystrophy Association. The institution of Dr. Shy has received research support from Charcot Marie Tooth Association. The institution of Dr. Shy has received research support from Applied Therapeutics.
Oscar L. Lopez, MD, FAAN Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck.
Craig M. Zaidman, MD Dr. Zaidman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for sarepta. The institution of Dr. Zaidman has received research support from Washington University in St Louis. The institution of Dr. Zaidman has received research support from Novartis.
Richard B. Lipton, MD, FAAN Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
John M. Ravits, MD, FAAN Dr. Ravits has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iris, Inc. Dr. Ravits has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Maze, Inc. Dr. Ravits has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Transposon, Inc. Dr. Ravits has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Libra, Inc. The institution of Dr. Ravits has received research support from NIH R21 Research Grant. The institution of Dr. Ravits has received research support from NIH R01 Research Grant. The institution of Dr. Ravits has received research support from FightMND Foundation Research Grant. The institution of Dr. Ravits has received research support from DOD Research Grant. Dr. Ravits has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH Office of Scientific Review.
Alan Pestronk, MD, FAAN The institution of Dr. Pestronk has received research support from RA. The institution of Dr. Pestronk has received research support from Fulcrum. The institution of Dr. Pestronk has received research support from Acceleron. The institution of Dr. Pestronk has received research support from Biogen. The institution of Dr. Pestronk has received research support from Jain. The institution of Dr. Pestronk has received research support from Sanofi. The institution of Dr. Pestronk has received research support from Muscular Dystrophy Association. Dr. Pestronk has received intellectual property interests from a discovery or technology relating to health care.
Joseph J. Higgins, MD, FAAN No disclosure on file
Ana C. Felix, MD, FAAN Dr. Felix has nothing to disclose.
Zheng Fan, MD Dr. Fan has nothing to disclose.
Stefania Corti, MD, PhD Dr. Corti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Corti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Corti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta.
Steven G. Younkin, MD, PhD No disclosure on file
Alice Chen-Plotkin, MD Dr. Chen-Plotkin has received intellectual property interests from a discovery or technology relating to health care.
Patrice Whitehead No disclosure on file
Gary W. Beecham, PhD The institution of Dr. Beecham has received research support from NIH. The institution of an immediate family member of Dr. Beecham has received research support from NIH.
Shifang Liu No disclosure on file
Shawna Feely, MS, CGC No disclosure on file
Izabela Karbassi No disclosure on file
Jonathan Haines, MD No disclosure on file
Adam Naj, PhD No disclosure on file
Thomas J. Montine, MD, PhD Dr. Montine has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Enable Medicine. Dr. Montine has stock in Enable Medicine. The institution of Dr. Montine has received research support from NIH. The institution of Dr. Montine has received research support from MJFF. Dr. Montine has received intellectual property interests from a discovery or technology relating to health care. Dr. Montine has received publishing royalties from a publication relating to health care.
Martin A. Kohli No disclosure on file
Emanuele Frattini No disclosure on file
Jon B. Toledo No disclosure on file
Matthew Harms, MD Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Harms has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Muscular Dystrophy Association. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Invitae. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Variant Bio. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Dr. Harms has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Littlepage Booth. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for O'Connor First. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Searcy Denney. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Ford, Parshall & Baker LLC . The institution of Dr. Harms has received research support from ALS Association. The institution of Dr. Harms has received research support from Ionis. The institution of Dr. Harms has received research support from ALS Finding a Cure. The institution of Dr. Harms has received research support from Target ALS.
John Powers No disclosure on file
Susan A. Eaton, PharmD No disclosure on file
Kym Boycott No disclosure on file
Corey McMillan, PhD Dr. McMillan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. McMillan has received research support from Biogen. The institution of Dr. McMillan has received research support from NIH.
Christopher Olm No disclosure on file
John Woulfe, MD, PhD No disclosure on file
Dennis E. Bulman, PhD No disclosure on file
Khalida Liaquat No disclosure on file
Conrad Weihl, MD, PhD Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Casma therapeutics. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abata. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Weihl has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acceleron. Dr. Weihl has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Wilson Elser Moskowitz Edelman & Dicker LLP.
Ericka P. Greene, MD, FAAN Dr. Greene has received personal compensation for serving as an employee of Argenx. Dr. Greene has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion, Inc. Dr. Greene has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylx. Dr. Greene has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Greene has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis . Dr. Greene has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for ABPN.
Jordan S. Dubow, MD Dr. Dubow has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Avadel Pharmaceuticals.
Michaela Kachadoorian No disclosure on file
Jeffrey Skolnick No disclosure on file
Mu Gao No disclosure on file
Konstantin E. Balashov, MD, PhD, FAAN Dr. Balashov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech.
Yael Shiloh-Malawsky, MD Dr. Shiloh-Malawsky has nothing to disclose.
David Irwin, MD The institution of Dr. Irwin has received research support from NIH. The institution of Dr. Irwin has received research support from Prevail. The institution of Dr. Irwin has received research support from Passage Bio. The institution of Dr. Irwin has received research support from Alector. The institution of Dr. Irwin has received research support from Transposon. The institution of Dr. Irwin has received research support from Denali.
Gerard Schellenberg, PhD No disclosure on file
Christiane Wegner, MD No disclosure on file
Timothy Cunniff, PharmD Dr. Cunniff has received personal compensation for serving as an employee of Paragon Biosciences. Dr. Cunniff has stock in Harmony Biosciences. Dr. Cunniff has stock in Emalex Biosciences.
Richard A. Macdonell, MD, FAAN Dr. Macdonell has nothing to disclose.
James M. Meyer, PharmD No disclosure on file
Andreas Lysandropoulos Andreas Lysandropoulos has nothing to disclose.
Stephen Wanaski, PhD Dr. Wanaski has received personal compensation for serving as an employee of Paragon Biosciences. Dr. Wanaski has stock in Paragon Biosciences. Dr. Wanaski has stock in Emalex Biosciences.
Nicholas J. Everage No disclosure on file
Claudia Prada No disclosure on file